Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls

JAMA

Volumn 296, Issue 7, 2006, Pages 863-865

  Liu, Albert Y ^a,b,d   Grant, Robert M ^b,c   Buchbinder, Susan P ^a,b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AIDS Office San Francisco   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PLACEBO; TENOFOVIR;

CHEMOPROPHYLAXIS; DISEASE CONTROL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR;

EID: 33747135726     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.7.863     Document Type: Note

References (27)

1. WHO Joint United Nations Programme on HIV/AIDS. 2006 Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2006.
2. Youle M, Wainberg MA. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic Ill). 2003;2:102-105.
3. AIDS Vaccine Clearinghouse. PrEP watch. http://www. aidsvaccineclearinghouse.org/prepwatch. Accessed June 6, 2006.
4. Garcia-Lerma J, Otten RA, Qari S, et al. Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colo.
5. Marchione M. AIDS drugs show prevention promise. ABC News Health Web site. March 28, 2006. http://abcnews.go.com/Health/wireStory?id=1775334. Accessed June 6, 2006.
6. Keegan A. Existing HIV drug holds promise for prevention. Southern Voice. April 7, 2006. http://www.sovo.com/2006/4-7/news/national/truvada.cfm.
7. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonomethoxypropyl)adenine. Science. 1995;270:1197-1199.
8. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265-4273.
9. Van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS. 1998;12:F79-F83.
10. Van Rompay KK, McChesney M, Aguirre NL, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001;184:429-438.
11. Schechter M, Lago R, Ismerio R, Mendelsohn A, Harrison L. Acceptability, behavioral impact, and possible efficacy of post-sexual-exposure chemoprophylaxis (PEP) for HIV. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002; Seattle, Wash.
12. Kindrick A, Tang H, Sterkenberg C, et al. HIV post-exposure prophylaxis following sexual exposure is started too late for optimal benefit. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, Colo.
13. Celum CL, Buchbinder SB, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV network for prevention trials vaccine preparedness cohort. J Infect Dis. 2001;183:23-25.
14. Costello D. AIDS pill as party drug? Los Angeles Times. December 19, 2005;sect F:F.1.
15. Cohen J. Protect or disinhibit? New York Times Magazine. January 22, 2006. http://www.nytimes.com. Accessed June 6, 2006.
16. Johnson J, Van Rompay K, Delwart E, Heneine W. Rapid emergence of drug-resistant SIV in tenofovir-treated macaques. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, Colo.
17. Roland ME, Neilands T, Krone M, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005;41:1507-1513.
18. Heffelfinger J, Hanson D, Voetsch A, et al. Renal impairment associated with the use of tenofovir. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, Colo.
19. Guest J, Rimland D, Patterson B, Desilva K. Tenofovir-induced nephrotoxicity in the first year of therapy. Paper presented at: 13th Conference on Retroviruses and Opportunistic Infections, February 5-8, 2006; Denver, Colo.
20. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease. Clin Infect Dis. 2006;42:283-290.
21. Gallant JE, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. JAMA. 2004;292:191-201.
22. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006;166:49-56.
23. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421-1425.
24. Mondou E, Sorbel J, Anderson J, et al. Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. Clin Infect Dis. 2005;41:e45-e47.
25. US Food and Drug Administration. Viread. US Food and Drug Administration Web site. http://www.fda.gov/medwatch/safety/2005/MAY_PI/Viread_PI.pdf. Accessed June 6, 2006.
26. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Recomm Rep. 2005;54(RR-2):1-20.
27. Osborne D. Can drugs prevent HIV? Gay City News. April 27-May 3, 2006. http://www.gaycitynews.com/gcn_517/candrugspreventhiv.html. Accessed June 6, 2006.